Navigation Links
Antibody Technologies and Attrition Rates - An Industry Analysis 2013
Date:4/16/2013

DUBLIN, Ireland, April 16, 2013 /PRNewswire/ --

Research and Markets announces the addition of "Antibody Technologies and Attrition Rates - an industry analysis 2013" to its catalogue.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The report Antibody Technologies and Attrition Rates - an industry analysis 2013 is based on the identification of the antibody generation technologies of 504 naked antibodies in clinical or market stages. Information was retrieved from scientific and corporate publications as well as from patent and legal literature. The report provides descriptive statistics of the 504 naked antibodies and their status during the study period of January 1, 2013 to February 28, 2013. The antibodies are categorized as active during the study period or discontinued during or before the study period. Attrition rates were calculated across a number of variables.

Descriptive statistics of the 504 naked antibodies include the following variables:

- Unique antibody identifiers (drug codes; generic name; brand name)
- Antibody format (full length, Fab, scFv, VH/VL, nanobody, bispecific, cocktail/polyclonal)
- In vitro antibody generation technologies (display technologies from CAT, Dyax, Morphosys, BioInvent, Domantis, Genentech, others)
- In vivo antibody generation technologies (chimeric, primatized, nanobodies, deimmunized, human engineered, humaneered, humanized, XenoMouse, HuMab mouse, KM mouse, VelocImmune mouse, human B-cell derived)
- Animal species of parental wild-type antibody (mouse, rat, rabbit, hamster, cynomolgus monkey, camelid)
- Antibody status (active/discontinued)
- Year of failure
- Reason for failure (efficacy, pharmacokinetics/ADME; safety; technical, business, next generation, inactivity)
- Target
- Immunoglobulin class and IgG isotype
- Highest phase
- Therapeutic area of lead indication
- Companies (developer, licensor/originator)

An Antibody Data Sheet was prepared for each unique antibody containing the retrieved information and the source of information in the form of a scientific reference or a hyperlink leading to the website from which the information was obtained.

The analysis essentially evaluated the question whether there are differences in clinical attrition rates between in vitro and in vivo antibody generation technologies as well as within the different in vitro and in antibody generation technologies. Attrition rate was defined as the percentage of failed antibodies of all active and inactive antibodies.

Reasons To Buy

Benefits from the data and the analysis include:

- Understand the historical and present state of the art use of antibody technologies;
- Learn the success rate of each antibody generation technology;
- Understand the reasons for failure of antibodies in clinical development;
- Appreciate the relative value of generic and of IP protected antibody technologies;
- Know which antibody technologies are using your competitors;
- Know the preferred antibody formats, IgG isotypes, development indications, parental wild-type animal species.
- Learn the influence of the target for the success rate of the selected antibody technology.

Key Topics Covered

Table of Contents

1 Executive Summary and Discussion

2 Introduction

3 Methodology

4 Results
4.1 Use of antibody technologies
4.2 Attrition rates
4.3 Reasons for failure
4.4 Antibody generation technologies and targets
4.5 Antibody technologies and antibody formats
4.6 Parental animal species of in vivo generated antibodies
4.7 Immunoglobulin class and isotype vs. antibody technology
4.8 Antibody technology and therapeutic areas
4.9 Attrition rates of antibodies in therapeutic areas
4.10 Benchmark analysis: big pharma and biotech antibody technology preferences and attrition rates

5 Tables
6 Addendum: Antibody Data Sheets

For more information please visit Research and Markets.

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contact Details

Research and Markets
Laura Wood , Senior Manager.
press(at)researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
2. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
3. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
4. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
5. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
6. Monoclonal Antibody Industry 2013 Global and China Market Analysis in New Research Report at RnRMarketResearch.com
7. AnaptysBio Develops Novel Antibody Scaffold With Extreme Thermostability
8. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
9. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
10. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
11. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):